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Abstract 
The role of donor CMV serostatus in the setting of non T-cell depleted haplo-HSCT with post-transplant cyclophosphamide 
(PT-Cy) has not been specifically addressed so far. Here we analyzed the impact of the donor CMV serological status on the 
outcome of 983 CMV seropositive (CMV+), acute leukemia patients receiving a first, non T-cell depleted haplo-HSCT 
registered in the EBMT database. The 1-year NRM was 21.3% (95% CI: 18.4–24.8) and 18.8% (95% CI: 13.8–25.5) in the 
CMV D+/R+ and D−/R+ pairs, respectively (p = 0.40). Similarly, 1-year OS was 55.1% (95% CI: 50.1–58.0) and 55.7% 
(95% CI: 48.0–62.8) in the same groups (p = 0.50). The other main outcomes were comparable. No difference in NRM nor 
OS was observed after stratification for the intensity of conditioning and multivariate anaysis confirmed the lack of 
significant association with NRM or OS. In conclusion, the choice of a CMV-seronegative donor did not impair early 
survival of CMV-seropositive patients with acute leukemia after a first, non T-cell depleted haploidentical HSCT and PT-Cy 
among this series of 983 consecutive patients. Future research may focus on the assessment of the hierarchy of all the donor 
variables. 
Introduction 
CMV status is a major determinant of transplant outcome [1–3] and it represents a key issue in the search for the optimal 
donor. In a recent megafile analysis from the Eur- opean Society for Blood and Marrow Transplantation (EBMT) on almost 
50,000 transplants [1] it was shown that CMV-seronegative (CMV−) patients receiving CMV- seropositive (CMV+) 
unrelated donor grafts had  decreased overall survival (OS) compared with CMV- 
donors, but no difference was observed when the donor was a HLA-identical sibling. The same analysis demonstrated that 
CMV+ patients receiving grafts from CMV+ unrelated donors had improved OS compared with CMV− donors only if 
they had received myeloablative conditioning (MAC). Thus, both the intensity of conditioning and the type of donor 
modulate the impact of donor CMV ser- ological status on the patient outcome [4, 5], the donor type possibly through the 
type of immunosuppression and the risk of associated graft-versus-host disease (GvHD). In addition, the negative effects 
of CMV infection on patient outcome might be amplified by the complications that may occur after the administration of 
the currently available antiviral drugs [6, 7]. 
While CMV serological status has been extensively studied for both HLA-identical siblings and unrelated donors, the 
significant worldwide increase in the use of haploidentical transplantation [8] has not resulted in anincrease of data about 
the impact of donor CMV status on patient outcome, despite the fact that the availability of a haploidentical family donor is 
generally greater than a HLA-identical sibling, and multiple haploidentical donors may be suitable for a single patient at 
the same time. CMV reactivation rates after non T-cell depleted haploidentical transplant range from 38 to 74% [9–13], 
contributing to the infection-related toxicity associated with this platform. Similarly, CMV disease is responsible for both 
morbidity and mortality in the same setting. Due to the CMV- associated toxicity and the greater availability of a haploi- 
dentical family donor (virtually 100% of the parents and offspring, 50% of siblings) compared with a HLA-identical 
sibling, a better definition of the role of donor CMV ser- ostatus on patients’ outcome after haploidentical transplan- tation 
may help to improve the search for the optimal haplo- donor. A recent analysis on 207 patient-donor pairs [14] failed to 
demonstrate any significant clinical impact of donor CMV serostatus after non T-cell depleted haploi- dentical 
transplantation using high-dose post-transplant cyclophosphamide (PT-Cy); however, it remains unknown if this lack of 
effect was real or due to the relatively low numbers in the series [14]. 
We thus conducted a registry-based analysis, on larger numbers, with the aim of estimating the impact of donor CMV 
serological status on the outcome of patients with acute leukemia who received a non T-cell depleted hap- loidentical 
transplantation and PT-Cy. Since a CMV- donor is assumed to be the best choice for a CMV- patient, the present analysis 
focuses on CMV+ patients only. However, a descriptive analysis on the CMV-negative patients trans- planted in the same 
period is also provided. 
  
  
Patients and methods 
 
The study was conducted on behalf of the Infectious Dis- ease Working Party and the Acute Leukemia 
Working Party of the EBMT. The EBMT is a voluntary working group of more than 500 transplant centers, 
mostly located in Europe, that are required to report all consecutive transplants and follow-up data once a year. 
All the items in the present analysis were collected through data retrieval from the EBMT registry (Med-A 
forms) after the approval by both Working Parties (WPs). No additional requests to centers were  made,  
except  for  the  variable  “donor  age”,   whose coverage was 54% at the time of first statistical analysis and 
reached 89% after the additional request. Informed consent was obtained before the transplantation procedure 
for all patients. 
The inclusion criteria were: diagnosis of acute leukemia, first allogeneic hematopoietic stem cell 
transplantation (HSCT) performed from 1st January 2010 to 31st December 
2015, patient CMV+ serological status, haploidentical donor (defined as the presence of an “HLA-
mismatched relative” with “≥2 HLA loci mismatches”), GvHD prophy- laxis including PT-Cy (defined as the 
presence of “cyclo- phosphamide given after day 0” among the drugs given for GvHD prophylaxis). The 
collected variables were as fol- lows: donor CMV serological status, age, gender; patient age, gender; disease, 
date of diagnosis, disease status at HSCT; drugs and their cumulative doses administered during the 
conditioning regimen, total body irradiation (Yes/No and respective dose), intensity of conditioning according 
to EBMT criteria, stem cell source, date of infusion, other drugs in addition to PT-Cy administered for GvHD 
prophylaxis, center activity (measured as the num- bers of haplo-HSCT/year that are included in the analysis 
from each center), neutrophil engraftment and date, acute GvHD, grading and date, chronic GvHD, severity 
and date, relapse date, death date, last follow-up, status and date, cause of death. 
 
Sample size definition 
 
A previous reported experience [14] showed a 1-year non- relapse mortality (NRM) of 24% and 31% in case 
of  CMV 
+ and CMV− donors, respectively for CMV+ patients. Assuming that such a difference actually exists, and 
taking into account the fact that more MAC regimens were expected to be present in this series of only acute 
leukemia compared to the previous one [14], a 50% increase in the NRM difference, i.e., 11%, would 
represent a reasonable and clinically meaningful difference to be detected, if pre- sent, between the groups. 
Considering a two-sided alpha = 
0.05 and a power = 0.80, our a priori calculation of sample size led to a minimum of n = 700 patients needed 
to verify this difference, meaning at least n = 525 and n = 175 in the CMV+ and CMV− donor groups 
respectively, according to an expected ratio of 3:1 [14]. These numbers were obtained from the haploidentical 
HSCT activity in Europe, therefore the analysis proved to be feasible and the study was approved by both the 
IDWP and ALWP boards. Some of the haplo-HSCTs reported in 2016 [14] are included in the present 
analysis. 
 
Statistical analysis 
 
The main characteristics of patients were described report- ing absolute and percentage frequencies in case of 
catego- rical variables and median and range for the continuous variables. Differences in the distribution 
between groups (donor CMV+ vs. CMV−) have been verified by t-test or U-Mann-Whitney test in case of 
continuous variables and using chi-square or Fisher exact test in case of categorical variables. 
  
 
Table 1 Characteristics in the D+ /R+ and D−/R+ groups. In bold 
are p-values <0.05. 
 
 
 
Table 1 (continued) 
CMV antibodies in donor Total 
 
 
p-value 
CMV antibodies in donor Total 
(N = 983) 
 
 
p-value  
 
CMV 
 
 
CMV 
(N = 983) 
 
 
N (%) 
CMV 
seronegative 
(N = 209) 
CMV 
seropositive 
(N = 774) 
N (%) seronegative 
(N = 209) 
seropositive 
(N = 774) 
 
 
 
  
N (%) N (%) 
 
 
N (%) N (%) 
 
 
Number of haplo-HSCTs per center 
 
Median 2.5 2.5 2.5 Ns 
Range 
N
o
 obs 
0.2–23.5 
209 
0.2–23.5 
774 
0.2–23.5 
983 
 
GvHD prophylaxis 
 
Female 80 (38.3) 340 (43.9) 420 (42.7) 
Tacro or CSA ± 
MMF 
192 (91.9) 720 (93.0) 912 (92.8) Ns 
Diagnosis Other 17 (8.1) 54 (7.0) 71 (7.2) 
AML 160 (77.3) 537 (70.0) 697 (71.6) 0.07 
 
 
ALL 43 (20.8) 220 (28.7) 263 (27.0)  
Other 4 (1.9) 10 (1.3) 14 (1.4)  NRM was estimated using the cumulative incidence 
Disease stage at transplant method, considering the relapse of the underlying disease as 
CR 126 (61.2) 516 (68.5) 642 (66.9) 0.047 competing event. A cause-specific Cox model was per- 
no CR 80 (38.8) 237 (31.5) 317 (33.1) formed in order to estimate the probability of NRM and OS 
Interval diagnosis to HSCT (months) 
Median 7.7 8.3 8.2 Ns 
Range 0.5–190.4 0.4–310.0 0.4–310.0 
N
o
 obs 209 774 983 
Patient age at HSCT 
according to the donor CMV status; this model has been 
adjusted by the main confounders taken into account, i.e., 
the variables resulted associated with the outcome of 
interest with a p-value < 0.20 in univariate and p < 0.05 in 
multivariate. Due to a potential distinct effect of donor 
according to the intensity of conditioning 
interaction between the intensity of con- 
n and the donor CMV serostatus was also 
post-hoc analysis was also performed, 
potential interaction between the  donor and  
the relationship between patient and latter  
extrapolated from age difference (see 
 
sion-free survival, relapse-free survival, 
acute and chronic GvHD, incidence of relapse 
l engraftment were estimated together with 
95% confidence interval (CI). The methods,  
Cox  model  and  the  cumulative 
hods were performed accordingly. 
analyses  were  performed  using  the statistical 
9.4 (SAS Institute Inc., Cary, NC,  USA). 
PB 86 (41.1) 356 (46.0) 442 (45.0) Ns  
BM 123 (58.9) 418 (54.0) 541 (55.0)  
TBI given     Results 
no 145 (69.7) 551 (71.6) 696 (71.2) Ns  
yes 63 (30.3) 219 (28.4) 282 (28.8)  Demographics 
Intensity of conditioning regimen 
MAC 115 (55.3) 506 (65.5) 621 (63.4) 0.01 A total of 983 CMV+ patients were identified, with a 
RIC 93 (44.7) 266 (34.5) 359 (36.6)  median follow-up of 1.6 years from haplo-HSCT (95% CI: 
1.4–1.8). Among these, n = 774 (79%) and n = 209 (21%) 
   had a CMV+ and CMV− donor, respectively (namely D 
Median 
Range 
N
o
 obs 
Donor age 
55.6 
2.3–74.0 
209 
41.7 
0.9–73.8 
774 
45.0 
0.9–74.0 
983 
<0.001 CMV serostatus 
[1], the possible 
ditioning regime 
investigated. A 
Median 34.3 38.1 37.1 <0.001 
investigating a 
Range 13.1–67.6 13.1–72.3 13.1–72.3 
CMV serostatus 
N
o
 obs 192 668 880 
donor, this 
further). 
Karnofsky or Lansky status 
Also progres
 
Median 90.0 90.0 90.0 
Ns 
incidence of 
Range 20.0–100.0 40.0–100.0 20.0–100.0 and of neutrophi 
N
o
 obs 
Categorized ka 
198 
rnofsky 
723 921 their respective 
Kaplan–Meier 
> = 90 130 (65.7) 465 (64.3) 595 (64.6) Ns incidence met 
< = 80 68 (34.3) 258 (35.7) 326 (35.4) All the 
Categorized source: BM+PB in BM group software SAS v. 
 
Patient gender 
Male 
 
113 (54.1) 
 
444 (57.4) 
 
557 (56.7) 
 
Ns 
Female 96 (45.9) 330 (42.6) 426 (43.3)  
Donor gender 
Male 
 
129 (61.7) 
 
434 (56.1) 
 
563 (57.3) 
 
Ns 
 
  
 
+/R+ and D−/R+ pairs), with an approximate 4:1 ratio. 
Baseline data are shown in Table 1. Interestingly, a sig- 
nificantly higher patient age, lower donor age, more 
reduced-intensity conditionings (RIC) and less complete 
remissions at transplant were observed in the D−/R+ group 
vs. the D+/R+ one. No other significant differences were 
present between the two groups. In addition to PT-Cy, the 
GvHD prophylaxis consisted of a calcineurin inhibitor 
(Tacrolimus or CsA) in association with Mycophenolate 
Mofetil in over 90% of patients, without differences between 
the two groups. Anti-thymocyte globulin was also used in n 
= 3 patients  (0.3% of  transplants).  To better illustrate  the 
putative relationship between patient and donor based on their 
respective ages, a scatter plot was built (Fig. 1). The plot 
identifies three clusters (the donor being a parent, a sibling or 
offspring) and shows more D−/R+ pairs when the donor is 
likely to be a child. This might explain the higher patient age 
and the lower donor age observed in this group, and is in line 
with the notion that CMV seropositivity increases with age in 
both SCT patients and their donors [15, 16]. 
 
Univariate analysis 
 
One-year NRM was 21.3% (95% CI: 18.4-24.8) and 18.8% 
(95% CI: 13.8–25.5) in the D+/R+ and D−/R+ groups, 
respectively (p = 0.40; Fig. 2a). NRM was not significantly 
different after stratification for the conditioning intensity, 
with estimates in the D+/R+ and D−/R+ groups of 19.8% 
(95%  CI:  16.3–24.0)  and  15.7%  (95%  CI:  10.0–24.8), 
p = 0.40,  after  MAC  and  24.3%   (95%  CI:  19.1–30.8) 
and  21.7%  (95%  CI:  14.2–33.2),  p = 0.5,  after  RIC. 
No significant interaction was  detected  between  the 
donor  CMV  status  and  the  intensity  of  conditioning   
(p = 0.80). 
One-year OS was similar in both groups: 55.1% (95% CI: 
50.1–58.0) and 55.7% (95% CI: 48.0–62.8) in the D+ /R+ 
and D−/R+ groups, respectively (p = 0.50, Fig. 2b). As for 
NRM, no significant interaction was detected between the 
donor CMV status and the intensity of conditioning with 
respect to OS (p = 0.60). Relapse-free survival and relapse 
incidence were 46.8% (95% CI: 42.8–50.7) and 47.8% (95% 
CI: 40.3–54.9), p = 0.40, and 29.9% (95% CI: 26.4–33.8) and 
30.8% (95% CI: 24.6–38.7), p = 0.80, at one year after haplo- 
HSCT; overall acute and chronic GvHD were 28.5% and 
26.3% (p = 0.2), and 27.7% and 29.7% (p = 0.7) respec- 
tively, with comparable proportions of severity between the 
groups: acute grade 2–4 was 58% and 47% of all graded acute 
GvHD events (p = 0.07 by chi-square), acute grade 3-4 was 
20% and 20% (p = 1.00) and extensive chronic GvHD was 
40% and 33% (p = 0.51) of all graded chronic GvHD events 
in the D+/R+ and D–/R+ groups, respectively. Neutrophil 
engraftment at 30 days was higher in the D-/R+ group: 91.1 
vs. 85.5%, p = 0.01. 
Multivariate analysis 
 
Multivariate analysis for NRM confirmed no statistically 
significant association with donor CMV serological status 
but there was a trend towards a higher NRM using a CMV- 
positive donor (Hazard Ratio, HR: 1.45, 95% CI: 0.97–
2.17, p = 0.07). Results did not significantly change when 
the model was built with either the adjustment for donor 
age or the insertion of the variable “relationship between 
patient and donor” in replacement of both patient and 
donor age (data not shown). The other significant variables 
associated with NRM were: patient age, perfor- mance 
status and center activity. 
Similarly, the donor CMV serological status was not 
significantly associated with OS, whereas the significant 
variables were: disease status at transplant, performance 
status and center activity. Results from the uni- and multi- 
variate analysis are shown in Table 2. 
Finally, the interaction test for both NRM and OS 
between patient-donor relationship and donor CMV status 
was not significant, meaning that the lack of significant 
association between donor CMV status and outcome is 
valid for all the three subgroups shown in Fig. 1. 
The observed unexpected difference in neutrophil 
engraftment was a posteriori investigated with a multi- 
variate model confirming the independent impact of donor 
CMV serostatus (p = 0.03), warranting further investigation 
in separate studies. 
 
CMV seronegative patients 
 
In the same period, a total of 237 CMV-negative patients 
received a non T-cell depleted haplo-HSCT with PT-Cy for 
acute leukemia and survival analysis shows 1-y OS = 
56.3% (95% CI: 48.3–63.4) and 1-y NRM = 17.7% (95% 
CI: 12.8–24.3) for the whole cohort. When analysed sepa- 
rately according to the donor CMV serological status, no 
significant differences were observed (p = 0.60 for OS, p = 
0.50 for NRM) and, similarly, OS and NRM were not 
significantly different among CMV-positive and CMV- 
negative patients (p = 0.30 for OS, p = 0.20 for NRM). 
 
Discussion 
 
We found similar outcomes using a CMV-positive or a 
CMV-negative donor on this registry-based cohort of 983 
consecutive CMV-positive patients affected by acute leu- 
kemia and receiving a first non T-cell depleted haplo-HSCT 
with PT-Cy. Due to the increase of haplo-HSCT activity in 
recent years, thanks to the introduction of PT-Cy [9, 17], 
these results are relevant and add a piece of information to 
the puzzle of the available criteria for the search of the best 
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Fig. 1 Putative patient-donor relationship based on the difference in age between the patient and the respective donorEach point represents a 
transplant that is located in the graph according to both the patient and the donor age. All transplants clustered into three subgroups, after the 
definition of a 18-years difference as the best cut–off: 1) the donor being > 18-years older than the patient (likely to be a parent; upper left); 2) the 
donor being > 18-years younger than the patient (likely to be a child-adolescent; lower right); 3) the donor age being less than 18-years older and 
less than 18-years younger (likely to be a sibling or even a cousin; middle). More CMV-negative donors are present in the subgroup 2), possibly 
explaining the higher patient age, the younger donor age and the use of more RIC among the D−/R+ pairs (see Table 1). Coefficients of 
correlation are shown here: donor old (r = 0.87, p < 0.0001; Coeff = 0.853, SD 0.0346, p < 0.0001), donor intermediate (r = 0.86, p < 0.0001; 
Coeff = 0.804, SD 0.0255, p < 0.0001), donor young (r = 0.75, p < 0.0001; Coeff = 0.725, SD 0.0359, p < 0.0001) (Color figure online) 
 
haploidentical donor. Indeed, whereas the donor CMV 
serological status has shown to be one of the most important 
determinants of patient outcome after transplantation from 
an unrelated donor (URD) [1, 4], this has not been inves- 
tigated for the most recent platform of non T-cell depleted 
haplo-HSCT using PT-Cy. Since physicians could face with 
multiple available family haploidentical donors, we believe 
that the question of how the donor CMV serostatus may 
contribute to the final choice of the donor is a relevant as 
well as practical topic. Here we found similar NRM and OS 
for the D+/R+ and D−/R+ pairs, indicating that the choice 
of a CMV-positive or negative donor led to comparable 
outcomes, with a median follow-up of 1.6 years from haplo- 
HSCT. In the previous EBMT analysis of donor serostatus 
influence on outcome, almost 9000 patients undergoing 
URD HSCT were included [1] and we cannot exclude that a 
study on haplo-HSCT and PT-Cy using a larger population 
might have detected an impact of donor serostatus. It is 
unknown if the same conclusions might be applicable for 
other diseases (e.g., lymphoma), and a separate analysis or 
an implementation of the present one by the integration of 
data from other diseases would be useful to answer this 
question. 
A possible explanation of the results lies in the char- 
acteristics of GvHD prophylaxis and of the immune 
reconstitution after non T-cell depleted haplo-HSCT with 
PT-Cy [18], which is different from what is generally seen 
in the URD setting, where a more extensive and prolonged 
immune suppression is often present, due to the frequent 
use of in vivo T-cell depletion [4, 19] and/or to a higher 
incidence of GvHD compared with non T-cell depleted 
haplo-HSCT and PT-Cy [20, 21], leading to the adminis- 
tration of additional immune-suppressive treatments. Here 
we did not observe a detrimental impact of a CMV mis- 
match between patient and donor and this might reflect 
more favorable immunological conditions after transplant, 
compared with the unrelated setting. As an additional 
observation, the low incidence of severe chronic GvHD 
after non T-cell depleted haplo-HSCT and PT-Cy [22] is 
likely to account, at least in part, for the observed results. 
Importantly, the lack of a significant association between 
the donor CMV serostatus and outcome was confirmed 
irrespectively of the conditioning regimen, and this is worth 
noting because of the well-known association between the 
intensity of conditioning and transplant mortality [23]. 
The use of PT-Cy has been reported also in the HLA- 
matched, related or unrelated setting, initially by the same 
authors from Baltimore [24] and thereafter by other groups 
[25–29]. To our knowledge, the impact of CMV serostatus 
has not been elucidated in this type of transplant platforms 
and deserves to be explored, giving the increasing use of 
PT-Cy in the HLA-matched setting, too. 
We acknowledge some limitations, such as the retro- 
spective nature of the analysis, and the lack of some rele- 
vant variables currently used for the choice of donor, such 
as the AB0-blood group matching [30, 31], or the body 
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Fig. 2 Non relapse mortality a 
and Overall Survival b for D+ 
/R+ vs. D−/R+ pairs (Color 
figure online) 
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weight [32]. The unexpected finding of a higher NRM after 
a CMV-matched donor in multivariate analysis might be 
explained by the potential threat represented by the intro- 
duction of a second CMV strain from the donor in the 
absence of T cells, or by the notion of the immune senes- 
cence that is associated with CMV seropositivity [33], 
although these speculations should be further confirmed. As 
a consequence, caution is needed when interpreting the 
multivariate results since, although the donor age has been 
adequately taken into account, other, unknown or non- 
evaluated variables may actually have affected the out- 
comes or some confounding factors may have been 
underestimated. The descriptive and comparative data on 
CMV-negative patients treated in the same period suggest 
that their outcome is not significantly different, however, 
any conclusion may be premature at this stage, due to the 
relatively low numbers (n = 237). As a final consideration, 
we cannot exclude that a difference of less than  11%  
exists between the two CMV groups and it has not been 
detected here because of the size of the study cohort, 
therefore the question might benefit from a larger cohort 
analysis. 
Nevertheless, this is the first large study addressing this 
specific topic and the results suggest that the choice of a 
CMV-mismatched donor does not have a detrimental effect 
on the patients outcome after haplo-HSCT. This result was 
confirmed for both RIC and MAC, and also for the three 
subgroups shown in Fig. 1, when the donor is likely to a 
parent (left), a sibling (occasionally a cousin; middle) and a 
child (right), respectively. A very recent analysis, investi- 
gating several variables in the context of AML/MDS 
patients receiving haplo-HSCT with the aim of building a 
predictive model, did not find donor CMV serostatus as a 
predictor of outcome [34], in line with our findings. Like- 
wise, recipient CMV serostatus and CMV matching have 
been evaluated as a covariates in other series of haplo- 
HSCT with PT-Cy [10, 20, 35] and the matching did not 
significantly impact on outcomes, although these studies 
were not specifically designed for that and lower transplant 
numbers were analysed. 
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Table 2 Uni-variate and multivariate analysis on NRM and OS. In bold are p-values <0.05. 
Non relapse mortality Overall survival 
 
 Univariate   Multivariate   Univariate   Multivariate  
HR (95% CI) p value  HR (95% CI) p value  HR (95% CI) p value  HR (95% CI) p value 
CMV serological status            
D−/R+ pairs 1 0.37  1 0.07  1 0.4603   0.1757 
D+/R+pairs 1.19 (0.81–1.72)   1.45 (0.97–2.17)   1.09 (0.87–1.40)   1.18 (0.92–1.49)  
Patient gender            
Male 1 0.156      ns    
Female 1.24 (0.92–1.67)           
Donor gender            
Male 1 0.0865     1 0.1017    
Female 0.76 (0.56–1.04)      0.86 (0.71–1.03)     
Age at HSCT            
10 year increment 1.51 (1.05–1.26) 0.0019  1.16 (1.06–1.27) 0.002   ns    
Disease stage at transplant 
CR 1 0.0023 1 <.0001  <.0001 
no CR 1.62 (1.19–2.22)  2.44 (2.02–2.94)  2.09 (1.70–2.57)  
Karnofsky or Lansky status 
Increment of 10 points 0.72 (0.65–0.79) <0.0001 0.71 (0.64–0.79) <0.0001 0.76 (0.71–0.81) <.0001 0.82 (0.76–0.88) <.0001 
Stem cell source         
PB  ns   1 0.1755   
BM     0.88 (0.73–1.06)    
TBI         
Yes 1 0.1127    ns   
No 1.33 (0.94–1.90)        
Conditioning regimen         
MAC 1 0.0856   1 0.0238   
RIC 1.30 (0.96–1.77)    1.24 (1.03–1.50)    
Number of SCT (every year) 
Increment of 10 0.77 (0.58–1.01) 0.0573 0.72 (0.54–0.96) 0.027 0.80 (0.68–0.94) 0.0075 0.72 (0.60–0.87) 0.0005 
GvHD prophylaxis        
Tacro or CSA ± MMF ns   0.80 (0.57–1.13) 0.1992   
Other    1    
Relationship patient/donor        
Old D/Young R 0.59 (0.38–0.93) 0.0717    ns   
Intermediate R/D 0.83 (0.59–1.16)        
Young D/Old R 1        
 
Importantly, here the advantage of using data from the 
registry lies in the ability to capture the data from real-life 
across the EBMT centers, thus showing a picture of what is 
currently done in clinical practice and what the outcomes 
are. As stated previously, we believe the results are worthy 
of note, given the increasing number of haplo-HSCTs and 
of the number of EBMT centers performing haplo-HSCTs 
[36]. Similarly to another recent EBMT report [22], a center 
effect has been observed for both NRM and OS  (see  
Table 2). 
In conclusion, after a median follow-up of 1.6 years 
from transplant, the choice of  a  CMV-negative  donor  
did not impair the outcome of CMV-positive acute 
leukemia patients after a first, non T-cell depleted haploi- 
dentical HSCT and PT-Cy among this series  of  almost 
one thousand, consecutive patients. Future directions may 
focus on the assessment of the hierarchy of all the donor 
variables as well as the inclusion of diseases other than 
leukemia. 
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